- $98.13m
- $152.41m
- $78.23m
Brief: OptiNose Receives Nasdaq Notice For Minimum Bid Price Non-Compliance
OptiNose Inc reports results for the quarter ended in June - Earnings Summary
OptiNose Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: Optinose Expanded Access To Xhance
OptiNose Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Optinose Inc Says FDA Approved Hikma As Additional Manufacturing Site For Finished XHANCE Units For Commercial Sale And Sampling
OptiNose Inc reports results for the quarter ended in December - Earnings Summary
Brief: Optinose Q4 revenue USD 19.865 million
OptiNose Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Optinose Says Optinose Us Entered Into Amendment No. 1 To Its Supply Agreement, Dated July 1, 2017
U.S. STOCKS ON THE MOVE-Vera Bradley, Shake Shack, 2seventy Bio
U.S. STOCKS ON THE MOVE-Citigroup, Regeneron, Ormat
Optinose falls as US FDA extends review of nasal spray
Brief: Optinose Announces 3-Month Extension Of FDA Review Period For The Supplemental New Drug Application For Xhance
Brief: OptiNose - PDUFA Goal Date For Xhance Chronic Rhinosinusitis SNDA Is Dec 16, 2023
OptiNose Inc reports results for the quarter ended in June - Earnings Summary
Brief: Optinose, Inc. Q2 EPS USD 0.02
OptiNose Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Optinose, Inc. posts Q2 revenue USD 19.5 million